# Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.

> **NCT03722680** · PHASE2 · SUSPENDED · sponsor: **UNICANCER** · enrollment: 80 (actual)

## Conditions studied

- Oxaliplatin-induced Peripheral Neuropathy

## Interventions

- **DRUG:** Riluzole
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03722680
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-10-28
- **Primary completion:** 2024-08-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 80 (ACTUAL)
- **Why stopped:** Lack of treatment, sponsor decision.
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03722680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03722680, "Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03722680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*